FLT4 antibody (Extracellular Domain) (Biotin)

Catalog No. ABIN1589800

This Mouse Monoclonal antibody specifically detects FLT4 in WB, ELISA and IP. It exhibits reactivity toward Human.

Quick Overview for FLT4 antibody (Extracellular Domain) (Biotin) (ABIN1589800)

Target: FLT4 (Fms-Related Tyrosine Kinase 4 (FLT4))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This FLT4 antibody is conjugated to Biotin

Application: Western Blotting (WB), ELISA, Immunoprecipitation (IP)

Clone: 1(9D9)

Product Details anti-FLT4 Antibody (Biotin)

Binding Specificity: Extracellular Domain

Purpose: VEGFR-3/FLT-4 antibody

Specificity: Recombinant human Vascular Endothelial Growth Factor Receptor 3 (rh VEGFR-3/FLT-4) extracellular domain

Cross-Reactivity (Details): The unconjugated antibody will detect native human VEGFR-3/FLT-4 in ELISA experiments.

Characteristics: Chromosomal location: 5q35.3
The antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified recombinant human Vascular Endothelial Growth Factor Receptor 3 (rh VEGFR-3/FLT-4) extracellular domain. VEGFR-3/FLT-4 mediates the angiogenic activity of VEGF-C and VEGF-D on lymphatic endothelial cells.

Purification: The IgG1 fraction of the hybridoma supernatant was purified by Protein G affinity chromatography and then biotinylated using a standard protocol. VEGFR-3/FLT-4, belongs to the class III subfamily of receptor tyrosine kinases.

Immunogen: recombinant human Vascular Endothelial Growth Factor Receptor 3 (rh VEGFR-3/FLT-4) extracellular domain

Isotype: IgG1

Application Details

Application Notes: WB: Use at 2-5 μg/mL, ELISA: Use at 1-10 μg/mL, IP: use at 2-10 μg/mL.

Restrictions: For Research Use only

Handling

Format: Lyophilized

Reconstitution: Centrifuge vial prior to opening. Reconstitute in sterile water to a concentration of 0.1-1.0 mg/mL.

Buffer: PBS, BSA (50x), 0.02 % sodium azide

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Centrifuge vial prior to opening.

Storage: 4 °C,-20 °C

Storage Comment: The lyophilized antibody is stable for at least 2 years at -20°C. After sterile reconstitution the antibody is stable at 2-8°C for up to 6 months. Frozen aliquots are stable for at least 6 months when stored at -20°C. Addition of a carrier protein or 50% glycerol is recommended for frozen aliquots.

Expiry Date: 24 months

Target Details for FLT4

Target: FLT4 (Fms-Related Tyrosine Kinase 4 (FLT4))

Alternative Name: VEGFR-3/FLT-4

Background: Vascular endothelial growth factor receptor-3, FLT4, PCL, LMPH1A, VEGFR3, fms-related tyrosine kinase 4,The recombinant mature sVEGFR-3/FLT-4 is a glycosylated monomeric protein. The sVEGFR-3/FLT-4 monomers have a mass of approximately 120 kDa. The soluble receptor protein consists of all 7 extracellular domains (Met1-Glu774). All three VEGF receptors belong to the class III subfamily of receptor tyrosine kinases (RTKs) characterised by the seven immunoglobulin-like loops in the extracellular domain. The expression of VEGFR-1 to -3 is almost exclusively restricted to hematopoietic precursor cells, vascular and lymphatic endothelial cells and to the monocyte/macrophage lineage. They play key roles in vasculogenesis, hematopoiesis, angiogenesis and lymphangiogenesis. The FLT-4 cDNA encodes a 1298 amino acid (aa) residue precursor protein with a 23 aa residue signal peptide. Mature VEGFR-3/FLT-4 is composed of a 751 aa residue extracellular domain, a 22 aa transmembrane domain and a 482aa residue cytoplasmic domain. Both VEGF family members VEGF-C and VEGF-D have been shown to bind and activate VEGFR-3/FLT-4. The Flt-4 gene is widely expressed in the early embryo but becomes restricted to the lymphatic endothelial a latter stages of development. It is important for lymphangiogenesis.

Gene ID: 2324

NCBI Accession: NM_002020

UniProt: P35916

Pathways: RTK Signaling, Signaling Events mediated by VEGFR1 and VEGFR2, VEGF Signaling